This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Comparison Between Oxomemazine, Guaifenesin and Potassium Iodate Versus Guaifenesin Monotherapy in Acute Cough Treatment

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified February 2013 by EMS.
Recruitment status was:  Recruiting
Information provided by (Responsible Party):
EMS Identifier:
First received: December 8, 2010
Last updated: February 26, 2013
Last verified: February 2013
The purpose of this study is evaluate if efficacy of a combination dose of oxomemazine, guaifenesin and potassium iodate is superior than guaifenesin monotherapy in acute cough treatment.

Condition Intervention Phase
Cough Drug: Syrup of oxomemazine, guaifenesin and potassium iodate Drug: Syrup of guaifenesin Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Multicentric, Randomized, Open-label Trial to Evaluate the Superiority of Fixed Dose Combination of Oxomemazine, Guaifenesin and Potassium Iodate to Guaifenesin Monotherapy in Acute Cough Treatment

Resource links provided by NLM:

Further study details as provided by EMS:

Primary Outcome Measures:
  • Reduction/improvement of cough symptoms [ Time Frame: DAY 7 ]
    The reduction of cough symptoms will be evaluated by comparative score index basal and final score

Secondary Outcome Measures:
  • Tolerance [ Time Frame: DAY 7 ]
    Adverse events will be collected and followed in order to evaluate safety and tolerability

Estimated Enrollment: 120
Study Start Date: February 2013
Estimated Study Completion Date: September 2013
Estimated Primary Completion Date: July 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: DRUG 1
Syrup of oxomemazine, guaifenesin and potassium iodate
Drug: Syrup of oxomemazine, guaifenesin and potassium iodate
5ml each 4 hours
Active Comparator: DRUG 2
Syrup of guaifenesin
Drug: Syrup of guaifenesin
5ml each 4 hours

Detailed Description:


  • Open-label, superiority, prospective, parallel group, intent to treat trial
  • Experiment duration: 7 days
  • 3 visits (days 1, 2 and 7)
  • Reduction cough symptoms
  • Adverse events evaluation

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patients must be able to understand the study procedures agree to participate and give written consent.
  2. Patients with productive cough as result an acute URTI (i.e., cold or flu) or allergic cough in the last 10 day.
  3. Cough score superior to 3.

Exclusion Criteria:

  1. Pregnancy or risk of pregnancy.
  2. Lactation.
  3. Fever above 38º C.
  4. Patients with bacterial infections of the upper respiratory tract.
  5. Any pathology or past medical condition that can interfere with this protocol.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01257243

Contact: Pesquisa Clínica 551138879851

Beneficência Nipo Brasileira de São Paulo - Hospital Nipo Brasileiro Recruiting
São Paulo, Brazil, 02189-000
Principal Investigator: Flávio Sano         
Sponsors and Collaborators
Study Director: Felipe Pinho, MD EMS
  More Information

Responsible Party: EMS Identifier: NCT01257243     History of Changes
Other Study ID Numbers: OGPGEMS0110
Study First Received: December 8, 2010
Last Updated: February 26, 2013

Keywords provided by EMS:

Additional relevant MeSH terms:
Respiration Disorders
Respiratory Tract Diseases
Signs and Symptoms, Respiratory
Signs and Symptoms
Chlorpheniramine, phenylpropanolamine drug combination
Potassium iodate
Respiratory System Agents
Adrenergic alpha-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Appetite Depressants
Anti-Obesity Agents
Autonomic Agents
Peripheral Nervous System Agents
Nasal Decongestants
Vasoconstrictor Agents
Antifungal Agents
Anti-Infective Agents processed this record on September 21, 2017